Navigation Links
Plato BioPharma Presenting Poster at the American Thoracic Society Conference
Date:5/4/2011

WESTMINSTER, Colo., May 4, 2011 /PRNewswire/ -- Plato BioPharma, Inc. (PBI) and Gilead Sciences, Inc. will be jointly presenting a thematic poster at the "Novel Therapeutics in Pulmonary Fibrosis" session at the 2011 American Thoracic Society (ATS) International Conference in Denver, Colorado on May 18, 2011.  The poster entitled Differing Effects of Ambrisentan and Bosentan on Pulmonary Fibrosis and Lung Mechanics Following Bleomycin Instillation will be presented by John Liles, PhD of Gilead Sciences, Inc. and  Craig Plato, PhD, CEO of Plato BioPharma, Inc.

"Human Idiopathic Pulmonary Fibrosis has no known effective treatment, and a dramatically poor prognosis," said Dr. Plato.  "The thematic research being presented at the 2011 ATS Conference provides insights into differential benefit of selective versus non-selective endothelin receptor antagonists in a robust preclinical model of this debilitating disease.  Importantly, for the first time, clinically-relevant functional endpoints such as arterial blood gases, lung function, and pulmonary hemodynamics have been utilized, in part, to reveal the benefit of selective endothelin receptor antagonism."

"One of PBI's key strengths is to leverage and impart our years of experience, expertise, and technology for every study we conduct.  This approach offers clients an advantage over a typical contract research organization or functional service provider relationship.  We strive to be an integral partner with our clients, delivering cutting-edge, high-resolution disease modeling and methods as well as insightful solutions to preclinical drug discovery challenges," said Dr. Plato.  "I believe our joint presentation with Gilead at this year's ATS shows our commitment to these goals and value-add for our clients."

Founded in 2009, Plato BioPharma, Inc is a leading preclinical contract research organization (CRO).  The company offers expert drug discovery and development capabilities in cardiovascular, renal, pulmonary, and hepatic disease therapeutic areas.  PBI provides an integrated research platform from the in-life phase through clinical chemistry, biomarker and histological analyses.  The company specializes in custom study design and execution engagements ranging from pharmacokinetics through disease model and proof-of-concept evaluation.  PBI is headquartered in Westminster, Colorado.


'/>"/>
SOURCE Plato BioPharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Ticagrelor Reduced Cardiovascular Deaths and Heart Attacks in ACS Patients Undergoing Heart Procedures: New Data from PLATO Trial
2. New PLATO Sub-Analysis of CABG Patients Presented at ACC
3. Plato BioPharma, Inc Appoints New Board Member
4. Plato BioPharma, Inc. Sponsors Novel Disease Model Award
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
7. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
8. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
9. Morria Biopharmaceuticals Plc Initiates Phase I Clinical Study of MRX-4 in Allergic Rhinitis
10. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
11. Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... , March 23, 2017  Mirabilis Medical, ... advanced medical technology for non-invasive surgery, announced today ... System for treatment of uterine fibroids throughout the ... had received approval from the US Food and ... the Mirabilis System in the United States.  The ...
(Date:3/24/2017)... , Mar 24, 2017 The Board ... the company,s Annual Report 2016 including the complete 2016 Annual ... and available on Nordic Nanovector,s website in the section Investor ... ... IR enquiries: Tone Kvåle, Chief Financial Officer Cell: +47-91-51-95-76 Email: ...
(Date:3/23/2017)... PUNE, India , March 23, 2017 ... are growing ageing population, increasing diabetic population, accelerating economic growth ... developments of this industry are higher life expectancy of ESRD ... potential in emerging markets. However, the expansion of the market ... ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... March 24, 2017 , ... ... of enhancements, upgrading their training and leads programs. , In February, 2017, Empower ... elite sales agents, Performance Partners is designed to teach how to maximize their ...
(Date:3/24/2017)... ... ... “End Time GPS”: a dauntless and enlightened study of the second-coming ... the creation of published author, Wesley Gerboth, a World War II veteran, with a ... Now, at age ninety-one, he shares the Wisdom God bestowed upon him in this ...
(Date:3/24/2017)... ... March 24, 2017 , ... “The Adventures of Joey, ... and silly dog who lives his life to the fullest, as God intended. “The ... author Patti Holmgren, a mother and grandmother pursuing her passion for writing, especially about ...
(Date:3/23/2017)... ... , ... The physicians of KSF Orthopaedic Center PA are proud to announce ... is located at 2255 E. Mossy Oaks Rd., Suite 440, Spring, Texas 77389 inside ... patients living in the north Houston area (The Woodlands, Conroe, Magnolia, Kingwood, Humble) with ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... Convention Center at 10 North Broadway Avenue, will be an educational and exciting ... practical instruction in the management of chronic pain. , Oklahoma is in a ...
Breaking Medicine News(10 mins):